Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Drugmakers race to find a place in the next wave of obesity drugs
08:00am, Saturday, 13'th Jun 2026
Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent Am
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About
12:32pm, Friday, 12'th Jun 2026
The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments.
Novo Nordisk Stock Up as UK Wegovy Pill Nod Eclipses Security Breach
10:11am, Friday, 12'th Jun 2026
NVO stock gains 3% as the United Kingdom becomes Europe's first country to approve the daily GLP-1 Wegovy weight-loss pill, overshadowing an IT security breach.
Novo Nordisk (NVO) Outpaces Stock Market Gains: What You Should Know
06:46pm, Thursday, 11'th Jun 2026
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $43.93, denoting a +2.62% move from the preceding trading day.
Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy
02:58pm, Thursday, 11'th Jun 2026
Eli Lilly (NYSE: LLY | LLY Price Prediction) and Novo Nordisk (NYSE: NVO) reported Q1 2026 results that pulled the
Novo Nordisk Advances Weight-Loss Portfolio With UK Approval Of Wegovy Tablet
01:34pm, Thursday, 11'th Jun 2026
On Thursday, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) approved Novo Nordisk A/S' (NYSE:NVO) Wegovy pill, clearing the company's first daily oral weight-management treatment
Novo Nordisk hit by cyber incident, probes data breach
11:45am, Thursday, 11'th Jun 2026
Novo Nordisk said on Thursday it has identified a security incident involving unauthorized access to a limited number of internal IT systems.
Novo Nordisk's Wegovy Weight Loss Pill Approved in the U.K.
11:42am, Thursday, 11'th Jun 2026
The U.K. regulator is the third regulatory authority to license the medicine as the Danish drugmaker seeks to regain its lead in the obesity market.
Why Pfizer Stock Popped Today
11:36am, Thursday, 11'th Jun 2026
Pfizer stock may not be cheap enough to buy yet, but it's certainly too cheap to sell.
Novo Nordisk A/S: IT Security incident at Novo Nordisk
11:30am, Thursday, 11'th Jun 2026
Bagsværd, Denmark, 11 June 2026 – Novo Nordisk A/S has identified an IT security incident involving unauthorised access to a limited number of internal IT systems. Upon learning of the incident, we
Employers Rethink GLP-1 Coverage
11:22am, Thursday, 11'th Jun 2026
Novo Nordisk (NVO, Financials) and Eli Lilly face a new challenge as some U.S. employers reconsider coverage for GLP-1 weight-loss drugs.The issue is cost. Even
Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK
11:03am, Thursday, 11'th Jun 2026
Approval is based on results from the OASIS 4 trial, which investigated semaglutide tablets 25 mg in adults living with obesity and overweight versus placebo in addition to diet and exercise Semagluti
The GLP-1 stock nobody is pricing in isn't a drugmaker
09:30am, Thursday, 11'th Jun 2026
Scott Galloway and Ed Elson laid out the math on Prof G Markets and it should make every fast food shareholder uneasy: roughly 30 million Americans, about 1 in 8 US adults, are now on GLP-1s, and the
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
07:14am, Thursday, 11'th Jun 2026
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect
Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases
06:03am, Thursday, 11'th Jun 2026
Some employers are planning to drop coverage of GLP-1 drugs for weight loss next year as more people take the medications, counteracting some savings from lower prices for Novo Nordisk's Wegovy and El
